Evidence map›Paper›PMID 37372944›Full record

ArticleInternational journal of molecular sciences2023

Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer's Disease.

Karen Zagorski, Olga King, Armine Hovakimyan, Irina Petrushina, Tatevik Antonyan, Gor Chailyan, Manush Ghazaryan, Krzysztof L Hyrc, Jean Paul Chadarevian, Hayk Davtyan and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Microglial activation states and their implications for Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Karen ZagorskiDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Olga KingDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Armine HovakimyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Irina PetrushinaInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.
Tatevik AntonyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Gor ChailyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Manush GhazaryanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Krzysztof L HyrcThe Hope Center of Neurological Disorders, Washington University School of Medicine, St Louis, MO 63110, USA.
Jean Paul ChadarevianInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.ORCID 0000-0002-2478-6592
Hayk DavtyanInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.ORCID 0000-0001-8554-6456
Mathew Blurton-JonesInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.ORCID 0000-0002-7770-7157
David H CribbsInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.
Michael G AgadjanyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Anahit GhochikyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Institute for Molecular Medicine · USUniversity of California, Irvine · USHope Center for Neurological Disorders · US

Funding

Multiple Approaches to Abeta Vaccination in Animal ModelsR01AG020241 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI AGADJANYAN, MICHAEL G, CRIBBS, DAVID HASTINGS · 2001 to 2016
$5.6M
Multiple Approaches to Abeta Vaccination in Animal ModelsRF1AG020241 · NIA · INSTITUTE FOR MOLECULAR MEDICINE · PI AGADJANYAN, MICHAEL G, CRIBBS, DAVID HASTINGS · 2018 to 2018
$3.3M
NIA NIH HHS R01 AG020241NIA NIH HHS RF1 AG020241NIH HHS R01-AG020241
6 · The paper itself

Abstract

Post-translationally modified N-terminally truncated amyloid beta peptide with a cyclized form of glutamate at position 3 (pE

Indexed as

Alzheimer DiseaseCancer VaccinesAmyloid beta-PeptidesAnimalsBrainDisease Models, AnimalImmunotherapyMiceMice, TransgenicPlaque, AmyloidPyrrolidonecarboxylic AcidAmyloid beta-PeptidesCancer VaccinesPyrrolidonecarboxylic AcidAlzheimer’s diseasepost-translational modificationpreventionpyroglutamatevaccine

Identifiers

PMID37372944
PMCPMC10298272
OpenAlexW4379519557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.